NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Clinical Practice Guidelines

Background:

• Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death in the US.
• Advanced stage at diagnosis presents a significant challenge, with <50% of patients surviving >5 years.
• Optimal outcomes depend on complete surgical resection and platinum-based chemotherapy.

Purpose of the Study:

• To review recent updates in NCCN Guidelines for ovarian cancer treatment.
• To highlight advancements in neoadjuvant chemotherapy and maintenance therapy.

Main Methods:

• Review of NCCN Guidelines Insights focusing on recent updates.
• Analysis of new recommendations for neoadjuvant chemotherapy and maintenance therapies.

Main Results:

• Incorporation of hyperthermic intraperitoneal chemotherapy (HIPEC) into neoadjuvant recommendations.
• Inclusion of PARP inhibitors and bevacizumab as maintenance therapy options for select patients.

Conclusions:

• Updated guidelines offer improved treatment strategies for epithelial ovarian cancer.
• Neoadjuvant chemotherapy and targeted maintenance therapies show promise for enhancing resectability and long-term survival.